I disagree that LP is responsible for stock price. These small bios are almost always shorted and down in these ranges. The market cap is not so far down, though obviously if they had a big pharma sponsor it would be higher. I doubt that is LP’s fault given the challenges in cell therapies absent bubble excitement. Then BP overpays for questionable technologies.
Dendritic cells were around for many years with many failures. The one success failed for operational and business reasons even when the treatment was ultimately validated. The market has been careful especially because of the bad actors who surround this sector, and spread bad press for a variety of reasons.